Cargando…
Insights into Chagas treatment based on the potential of bacteriocin AS-48
Chagas disease caused by the protozoan parasite Trypanosoma cruzi represents a significant public health problem in Latin America, affecting around 8 million cases worldwide. Nowadays is urgent the identification of new antichagasic agents as the only therapeutic options available, Nifurtimox and Be...
Autores principales: | Martín-Escolano, Rubén, Cebrián, Rubén, Martín-Escolano, Javier, Rosales, Maria J., Maqueda, Mercedes, Sánchez-Moreno, Manuel, Marín, Clotilde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447751/ https://www.ncbi.nlm.nih.gov/pubmed/30953804 http://dx.doi.org/10.1016/j.ijpddr.2019.03.003 |
Ejemplares similares
-
Preclinical studies of toxicity and safety of the AS-48 bacteriocin
por: Cebrián, Rubén, et al.
Publicado: (2019) -
Selenium Derivatives as Promising Therapy for Chagas
Disease: In Vitro and In Vivo Studies
por: Martín-Escolano, Rubén, et al.
Publicado: (2021) -
Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
por: Montalbán-López, Manuel, et al.
Publicado: (2020) -
Control of Propionibacterium acnes by natural antimicrobial substances: Role of the bacteriocin AS-48 and lysozyme
por: Cebrián, Rubén, et al.
Publicado: (2018) -
An Updated View of the Trypanosoma cruzi Life Cycle: Intervention Points for an Effective Treatment
por: Martín-Escolano, Javier, et al.
Publicado: (2022)